The presence of Vim+ CTCs in pretreatment patients was correlated with liver metastases and meanwhile confirmed to significantly related to patient’ poor prognosis which was consistent with previous studies reported by others on prostate cancer studies (Satelli et al. 2017). This evidence concerns the gene VIM and prostate carcinoma.